Recent advances in the treatment of gestational diabetes

Bibliography

• AMERICAN DIABETES: Gestational diabetes mellitus. Position statement. Blab. Care (2004) 27\(Suppl. 1):S88–S90.
   Google Scholar
• GREENE MF: Screening for gestational diabetes mellitus. N Engl. J. Med. (1997) 337:1625–1626.
   PubMed Web of Science ®Google Scholar
• HANNA FW, PETERS JR: Screening for gestational diabetes; past, present and future. Diabetic Med. (2002) 19:351–358.
   PubMed Web of Science ®Google Scholar
• KOUSSEFF BG: Gestational diabetes mellitus (class A): a human teratogen? Am. .1. Med. Genet. (1999) 83:402–408.
   PubMed Web of Science ®Google Scholar
• BEN-HAROUSH A, YOGEV Y, HOD M: Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet. Med. (2004) 21:103–113.
   PubMed Web of Science ®Google Scholar
• O'SULLIVAN JB, MAHAN CM: Criteria for the oral glucose tolerance test in pregnancy. Diabetes (1964) 13:278–285.
   PubMed Web of Science ®Google Scholar
• VOGEL N, BURNAND B, VIAL Yet al: Screening for gestational diabetes: Variation in guidelines. Eur. Obstet. Gynecol. Reprod. Biol. (2000) 91:29–36.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO Consultation, Geneva: WHO (1999).
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS: Clinical management guidelines for obstetrician-gynecologists. Gestational diabetes. ACOG Practice Bulletin 30. Obstet. Gynecol (2001) 98:525–538.
   Google Scholar
• CANADIAN DIABETES ASSOCIATIONCLINICAL PRACTICE GUIDELINES EXPERT COMMITTEE: Guidelines for prevention and management of diabetes in canada. Can. .1. Diabetes (2003) 27\(Suppl 2):599–5105.
   Google Scholar
• THE AUSTRALIAN DIABETES IN PREGNANCY SOCIETY: Gestational diabetes mellitus guidelines. Med. J. Australia (1998) 169:93–97.
   PubMed Web of Science ®Google Scholar
• AGARWAL MM, PUNNOSE J: Gestational diabetes; implications of variation in diagnostic criteria. Int. J. of Gynecol Obstet. (2002) 78:45–46.
   PubMed Web of Science ®Google Scholar
• BRODY SC, HARRIS R, LOHR K: Screening for gestational diabetes: a summary of the evidence for the US Preventive Services Task Force. Obstet. Gynecol (2003) 101:380–392.
   PubMed Web of Science ®Google Scholar
• KJOS SL, BUCHANAN TA: Gestational diabetes mellitus. N Engl. I Med. (1999) 341:1749–1756.
   PubMed Web of Science ®Google Scholar
• LANDO H: The new 'designer' insulins. Clinical Diabetes (2000) 18:154.
   Google Scholar
• GARCIA-BOURNISSEN F, FEIG DS, KOREN G: Maternal-fetal transport of hypoglycaemic drugs. Clio. Pharmacokinet. (2003) 42:303–313.
   PubMed Web of Science ®Google Scholar
• ••An outstanding review on the problems ofhypoglycaemic drugs in pregnancy.
   Google Scholar
• GAMSON K, CHIA S, JOVANOVIC L: The safety and efficacy of insulin analogs in pregnancy. .1. Matern. Fetal Neonatal Med. (2004) 15:26–34.
   PubMedGoogle Scholar
• ••Recent review on insulin safety inpregnancy.
   Google Scholar
• PEDERSEN J: Weight and length at birth of infants of diabetic mothers. Acta Endocrinol (1954) 16:330–342.
   PubMedGoogle Scholar
• GRECO P, VIMERCATI A, HYETT J et al.: The ultrasound assessment of adipose tissue deposition in fetuses of 'well controlled' insulin-dependent diabetic pregnancies. Diabet. Med. (2003) 20:858–862.
   PubMed Web of Science ®Google Scholar
• MIMOUNI F, MIODOVNIK M, SIDDIGI TA et al.: Perinatal asphyxia in of insulin-dependent diabetic mothers. Pediatr. (1988) 113:345–353.
   Web of Science ®Google Scholar
• GREENE MF: Oral hypoglycemic drugsfor gestational diabetes. N Engl. J. Med. (2000) 343:1178–1179.
   PubMed Web of Science ®Google Scholar
• SCHAEFER-GRAF UM, TA, XIANG A et al.: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by Type 2 and gestational diabetes. Am. .1. Obstet. Gynecol (2000) 182:313–320.
   Google Scholar
• SEWER M, NAYLOR CD, GARE DJ et al.: Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am. .1. Obstet. Gynecol (1995) 173:146–156.
   Google Scholar
• RUMBOLD AR, CROWTHER CA: Women's experiences of being screened for gestational diabetes mellitus. Aust. N Z Obstet. Gynaecol (2002) 24:131–137.
   Google Scholar
• HAPO STUDY COOPERATIVE RESEARCH GROUP: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int.j Gynaecol Obstet. (2002) 78:69–77.
   PubMed Web of Science ®Google Scholar
• PARRETTI E, MECACCI F, PAPINI M et al.: Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care (2001) 24:1319–1323.
   PubMed Web of Science ®Google Scholar
• JOVANOVIC L: Point: yes, it is necessaryto rely entirely on glycemic values for the insulin treatment of all gestational diabetic women. Diabetes Care (2003) 26:946–947.
   PubMed Web of Science ®Google Scholar
• DE VECIANA M, MAJOR CA, MORGAN MA et al.: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl. I Med (1995) 333:1237–1241.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, KJOS SL: Glucose monitoring in gestational diabetes: lots of heat, not much light. Diabetes Care (2003) 26:948–949.
   PubMed Web of Science ®Google Scholar
• DREXEL H, BICHLER A, SAILER S et al.: Prevention of perinatal morbidity by tight metabolic control in gestational diabetes mellitus. Diabetes Care (1988) 11:761–768.
   PubMed Web of Science ®Google Scholar
• TUROK DK, RATCLIFFE SD, BAXLEY EG: Management of gestational diabetes mellitus. Am. Fain. Physician (2003) 68:1767–1772.
   PubMed Web of Science ®Google Scholar
• DORNHORST A: Gestational diabetes: the unanswered questions. Clin. Nutr. (2003) 12:53–57.
   Google Scholar
• DORNHORST A, FROST G: The principles of dietary management of gestational diabetes: reflection on current evidence. Hum. Nutr. Diet (2002) 15:145–156.
   PubMed Web of Science ®Google Scholar
• LANGER 0: Management of gestationaldiabetes. Gin. Obstet. Cynecol (2000) 43:106–115.
   Google Scholar
• SCHOLL TO, HEDIGER ML, JI et al.: Gestational weight gain, pregnancy outcome, and postpartum weight retention. Obstet. Cynecol (1995) 86:423–427.
   Web of Science ®Google Scholar
• MOSES RG: The recurrence rate of gestational diabetes in subsequent pregnancies. Diabetes Care (1996) 19:1348–1350.
   PubMed Web of Science ®Google Scholar
• BRANKSTON GN, MITCHELD BE RYAN EA et al.: Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am. J. Obstet. Cynecol (2004) 190:188–193.
   Google Scholar
• REECE EA, HOMKO CJ: Diabetes mellitus in pregnancy. What are the best treatment options? Drug Sal (1998) 18:209–220.
   Google Scholar
• ••Very good review on the safety of drugsused in pregnancy.
   Google Scholar
• BHATTACHARYYA A, BROWN S, HUGHES S et al.: Insulin lispro and regular insulin in pregnancy. 0M(2001) 94:255-260.
   Google Scholar
• •Good overview of insulin lispro in pregnancy.
   Google Scholar
• MeFARLAND MB, LANGER 0, CONWAY DL et al.: Dietary therapy for gestational diabetes: how long is long enough? Obstet. Cynecol (1999) 93:978–982.
   Google Scholar
• GIUFFRIDA FMA, CASTRO AA, ATALLAH AN et al.: Diet plus insulin compared to diet alone in the treatment of gestational diabetes mellitus: A systematic review. Braz. I Med. Biol. Res (2003) 36:1297–1300.
   Web of Science ®Google Scholar
• NACHUM Z, BEN-SHLOMO I, WEINER E et al.: Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. Br. Med. (1999) 319:1223–1227.
   PubMed Web of Science ®Google Scholar
• MENON RK, COHEN RIVI, MA et al.: Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N Engl.' Med. (1990) 323:309–315.
   PubMed Web of Science ®Google Scholar
• BALSELLS M, CORCOY R, D et at Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care (1997) 20:1172–1175.
   PubMed Web of Science ®Google Scholar
• LANDAUER W, CLARK EM: Teratogenic interaction of insulin and 2-deoxy-D-glucose in chick development. Exp. Zool. (1962) 151:245–252.
   PubMedGoogle Scholar
• REAM JR, WEINGARTERN PL, PAPPAS AM: Evaluation of the prenatal effects of massive doses of insulin in rats. Teratology (1970) 3:29–32.
   PubMedGoogle Scholar
• PHELPS RL, SAKOL P, METZGER BE et al.: Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch. Ophthalmol (1986) 104:1806–1810.
   PubMed Web of Science ®Google Scholar
• BEST RM, CHAKRAVARTHY U: Diabetic retinopathy in pregnancy. Br. Ophthalmol (1997) 81:249–451.
   PubMed Web of Science ®Google Scholar
• MASS ON EA, PATMORE JE, BRASH PD et al.: Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet. Med. (2003) 20:46–50.
   PubMed Web of Science ®Google Scholar
• MECACCI F, CARIGNANI L, CIONI R et al.: Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Ear: Obstet. Cynecol Reprod Biol. (2003) 111:19–24.
   PubMed Web of Science ®Google Scholar
• DIAMOND T, KORMAS N: Possible adverse fetal effect of insulin lispro. N Engl. Med. (1997) 337:1009.
   PubMed Web of Science ®Google Scholar
• JOVANOVIC L, ILIC S, PETTITT DJ 3rd et al.: Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care (1999) 22:1422–1427.
   Google Scholar
• BOSKOVIC R, FEIG DS, L et al.: Transfer of insulin lispro across the human placenta: ha vitro perfusion studies. Diabetes Care (2003) 26:1390–1394.
   PubMed Web of Science ®Google Scholar
• KITZMILLER JL, MAINE, WARD B et al.: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care (1999) 22:874–876.
   PubMed Web of Science ®Google Scholar
• BUCHBINDER A, MIODOVNIK M, KHOURY J et al.: Is the use of insulin lispro safe in pregnancy? Matern. Fetal Neonatal Med. (2002) 11:232–237.
   Google Scholar
• LOUKOVAARA S, IMMONEN I, TRAMP KA et al.: Progression of retinopathy during pregnancy in Type 1 diabetic women treated with insulin lispro. Diabetes Care (2003) 26:1193–1198.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49:999–1005.
   PubMed Web of Science ®Google Scholar
• PETTITT DJ, OSPINA P, JW A et al.: Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care (2003) 26:183–186.
   PubMed Web of Science ®Google Scholar
• CIARALDI TP, CARTER L, SEIPKE G et al.: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. I Gin. Endocrinol Metab. (2001) 86:5838–5847.
   PubMed Web of Science ®Google Scholar
• HOLSTEIN A, PLASCHKE A, EGBERTS EH: Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet. Med. (2003) 20:779–780.
   PubMed Web of Science ®Google Scholar
• DEVLIN JT, HOTHERSALL L, WILKIS JL: Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabetes Care (2002) 25:1095–1096.
   PubMed Web of Science ®Google Scholar
• GRAY RS, COWAN P, STEEL JM et al.: Insulin action and pharmacokinetics in insulin treated diabetics during the third trimester of pregnancy. Diabet. Med (1984) 1:273–738.
   PubMedGoogle Scholar
• JOVANOVIC L: Optimization of insulintherapy in patients with gestational diabetes. Endocr. Pract. (2000) 6:98–100.
   PubMedGoogle Scholar
• MERLOB P, LEVITT 0, STAHL B: Oral antihyperglycemic agents during pregnancy lactation: a review. Paediatr. Drugs (2002) 4:755–760.
   PubMedGoogle Scholar
• FANELLI CG, B BOLLI GB: Sulphonylureas and pregnancy. Ear: J. Endocrinol (1998) 138: 615–616.
   PubMed Web of Science ®Google Scholar
• SMOAK IW, EMANUEL AN: Tolbutamide placental transfer, tissue distribution, and metabolic effects in murine embryos. Pharmacol Toxicol (1998) 82:203–208.
   PubMedGoogle Scholar
• HELLMUTH E, DAMM P,-PEDERSEN L: Congenital malformations in offspring of diabetic women treated with oral hypoglycaemic agents during embryogenesis. Diabet. Med. (1994) 11:471–474.
   PubMed Web of Science ®Google Scholar
• PIACQUADIO K, DR, MURPHY H: Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet (1991) 338(8771):866–869.
   PubMed Web of Science ®Google Scholar
• TOWNER D, KJOS SL, LEUNG B et aL: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care (1995) 18:1446–1451.
   PubMed Web of Science ®Google Scholar
• CHRISTESEN HB, MELANDER A: Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. Ear: J. Endocrinol (1998) 138:698–701.
   PubMed Web of Science ®Google Scholar
• KEMBALL ML, McIVER C, MILNER RD et al.: Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis. Child (1970) 45;243:696–701.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND HW, BEWSHER PD, CORMACK JD et al.: Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis. Child (1974) 49:283–291.
   PubMed Web of Science ®Google Scholar
• COETZEE EJ, JACKSON WP: Oralhypoglycaemics in the first trimester and fetal outcome. S. Air. Med. J. (1984) 21;65:635–637.
   Google Scholar
• ELLIOTT BD, LANGER 0, S et al.: Insignificant transfer glyburide occurs across the human . Am. Obstet. Cynecol. (1991) 165:807–812.
   Google Scholar
• KOREN G: Glyburide and fetal safety;transplacental pharmacokinetic considerations. Reprod. Toxicol (2001) 15:227–229.
   PubMed Web of Science ®Google Scholar
• NIEMI M, BACKMAN JT, M et al.: Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol Ther. (2001) 69:400–406.
   PubMed Web of Science ®Google Scholar
• SMIT JW, HUISMAN MT, TELLINGEN 0 et al.: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Gin. Invest (1999) 104:1441–1447.
   Google Scholar
• LANGER 0, CONWAY DL, BERKUS MD et al: A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl. J. Merl (2000) 19:343:1134–1138.
   Google Scholar
• KOREN G: The use of glyburide in gestational diabetes-an ideal example of 'bench to bedside'. Pediati: Res. (2001) 49:734.
   PubMed Web of Science ®Google Scholar
• LORD JM, FLIGHT IH, NORMAN RJ: Metformin in polycystic ovary syndrome: Systemic review and meta-analysis. Br. Med. J. (2003) 327(7421):951–953.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, KOBAYASHI S et al.: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril (2002) 77:520–525.
   PubMed Web of Science ®Google Scholar
• COETZEE E, JACKSON W: The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res. Clin. Pract. (1986) 1:281–287.
   Google Scholar
• HELLMUTH E, DAMM P, MOLSTED-PEDERSEN L: Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet. Med. (2000) 17:507–511.
   PubMed Web of Science ®Google Scholar
• STEEL JM, CAMPBELL IW: Oral hypoglycaemic agents in 188 diabetic. Diabet. Med. (2001) 18:604–605.
   PubMed Web of Science ®Google Scholar
• HAGUE WM, DAVOREN PM, OLIVER D et al.: Contraindications to use of metformin. Metformin may be useful in gestational diabetes. Br. Med. (2003) 326:762.
   Google Scholar
• SIMMONS D, WALTERS BN, JA et al.: Metformin therapy and diabetes in pregnancy. Med. J. Aust (2004) 180:462–464.
   PubMed Web of Science ®Google Scholar
• HAGUE WM, DAVOREN PM, McINTYRE D et al.: Metformin crosses the placenta: A modulator for fetal insulin resistance. Br. Med. J. (2003) 327:880–881.
   PubMedGoogle Scholar
• MOKDAD AH, BOWMAN BA, ES et al: The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 12:286:1195–1200.
   Google Scholar
• BELL DS: Type 2 diabetes mellitus: what is the optimal treatment regimen? Am. I Merl (2004) 116(Suppl. 5A):235–295.
   Google Scholar
• YARIS F, YARIS E, KADIOGLU M et al.: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol (2004) 18:619–621.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE: a-Glucosidase inhibitors. EndocrinoL Metab. Gin. North Am. (1997) 26:539–551.
   PubMed Web of Science ®Google Scholar
• ZARATE A, OCHOA R, M et al.: Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. CynecoL Obstet. Mex. (2000) 68:42–45.
   PubMedGoogle Scholar